Please select the eligibility criteria that correspond to the clinical trial below.
Title: Comparative Effectiveness of Pregnancy Failure Management Regimens
Brief Summary: The purpose of the study is to compare the effectiveness of combination treatment (mifepristone premedication plus single-dose misoprostol) to single-dose misoprostol (standard of care) for the management of early pregnancy failure.


Options:
A: Inclusion Criteria:

* no contraindications to misoprostol
* uterine size was not larger than 12 weeks
* there were no signs of severe infection
* haemodynamically stable
* in general good health
* willing to provide contact information

Exclusion Criteria:

* an IUD in place
* ectopic pregnancy
* aged below 18 years and had no accompanying adult to provide informed consent
B: Inclusion Criteria:

* single dead fetus up-to 12 weeks.
* no low lying placenta
* no scarred uterus
* no or mild bleeding
* no evidence of infection
* accepting to participate in the study.

Exclusion Criteria:

* Advanced hepatic diseases .
* Suspected molar pregnancy
* Ectopic pregnancy or pregnancy of unknown location
* Haemodynamically unstable with significant anaemia ie Hb\<10
* Uncontrolled severe asthma
* Chronic adrenal failure
* Known or suspected heart disease
* Glaucoma
* Haemoglobinopathies
* Haemorrhagic disorders and anti-coagulation therapy (aspirin accepted)
* Adrenal suppression and long term glucocorticoid therapy (may require corticosteroid)
* Patient living in remote areas with difficulty in accessing hospital
C: Inclusion Criteria:

* between 5 and 12 completed weeks gestation
* 18 years or older
* hemodynamically stable
* confirmed diagnosis of intrauterine embryonic/fetal demise or anembryonic gestation (ultrasound examination demonstrates a fetal pole without cardiac activity measuring between 5.3 and 40 mm or an abnormal growth pattern diagnostic of early pregnancy failure)
* willing and able to give informed consent

Exclusion Criteria:

* diagnosis of incomplete or inevitable abortion (absent gestational sac and/or active bleeding, open cervical os)
* contraindication to mifepristone (chronic corticosteroid administration, adrenal disease)
* contraindication to misoprostol (glaucoma, mitral stenosis, sickle cell anemia, or known allergy to prostaglandin)
* cardiovascular disease (angina, valvular disease, arrhythmia, or cardiac failure)
* most recent hemoglobin \<9.5 g/dL
* diagnosis of porphyria
* known clotting defect or receiving anticoagulants
* pregnancy with an intrauterine device (IUD) in place
* breastfeeding during the first 7 days of study participation
* unwilling to comply with the study protocol and visit schedule
* any evidence of viable pregnancy
* possibility of ectopic pregnancy
* known or suspected pelvic infection
* concurrent participation in any other interventional trial
D: The inclusion criteria:

* Patients to be female, aged 18-45 years
* Without previous dilatation and curettage
* Undergoing dilatation and curettage for the current delayed miscarriage
* All participants should be with normal liver/rental function and without systemic disease
* Agree to use adequate forms of contraception throughout the study
* Be in good compliance with the follow-up examination according to the study protocol.

The exclusion criteria:

* Known/suspected intolerance or hypersensitivity to hyaluronan or its derivatives
* Genital tract malformation
* Inflammation of genital tract or pelvic cavity, clinical evidence of cancer in genital tract
* Suspected genital tuberculosis
* Abnormal blood coagulation
* Medical histories of peripheral vascular disease, alcohol/drug abuse, and mental illness
* Acute or severe infection
* Autoimmune diseases.

Answer: C